Abstract Background -Eosinophils from asthmatic patients are known to release greater amounts of leukotrienes than normal eosinophils when stimulated by the calcium ionophore A23187. The effect of platelet activating factor (PAF) in priming eosinophils was investigated. Methods -Eosinophils were obtained from 18 asthmatic patients and 18 healthy donors. Cells separated by the Percoll gradients were incubated with PAF(C-18) for 30 minutes and then stimulated with the calcium ionophore A23187 (2.5 FM) for 15 minutes. The amount of leukotriene C4 (LTC4) in supernatants was measured using a combination of high pressure liquid chromatography and radioimmunoassay. Results -The mean (SD) amount of LTC4 released by eosinophils from asthmatic patients upon stimulation with the calcium ionophore A23187 alone was 27*9 (9.9) ng/ 106 cells (n=6). The amount of LTC4 released following stimulation with the calcium ionophore A23187 after pretreatment with PAF (1, 5, and 10 FM) was 57'2 (8.9), 75-1 (14.3), and 52*6 (10.7) ng/10' cells (n= 6), respectively. Trace amounts of LTC4 (0 9 (0 02) ng106 cells, n = 6) were detected in the supernatant of the cells after stimulation by PAF alone (5 FM). The amount of LTC4 released upon stimulation by calcium ionophore A23187 alone in eosinophils from healthy donors was 10-3 (3.7)ng/106 cells (n=4). The amounts of LTC4 released upon stimulation with calcium ionophore A23187 after pretreatment with PAF at concentrations of 1, 5, and IO pM were 11 9 (3.5), 17-8 (5.6), and 12-7 (5.1)ng/106 cells (n=4), respectively.
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Eighteen healthy donors aged 26 to 42 years with no history of bronchial asthma or other allergy, a negative skin test, and normal pulmonary function, gave their informed consent prior to the study. None was taking any medication.
The study was approved by the ethical committee of our institution.
MATERIALS
Hanks' balanced salt solution (HBSS), 5% fetal calf serum (FCS), and piperazine-N,N'-bis-(2-ethane-sulphonic acid) (PIPES) were purchased from Sigma Chemical Ltd Japan (Tokyo, Japan). PAF (1-o-octadecyl-2-o-acetylsn-glycero-3-phosphoryl-choline; C-18), and lyso-PAF (1 -o-hexadecyl-sn-glycero-3-phosphoryl-choline) were obtained from Sigma Chemical Ltd Japan (Tokyo, Japan), and 6% dextran T70 and Percoll solution were purchased from Pharmacia Fine Chemicals (Piscataway, New Jersey, USA).
COLLECTION OF BLOOD
Heparinised venous blood was collected from the subjects. Leucocytes were obtained by sedimenting five volumes ofblood with one volume of 6% dextran T70 in normal saline for one hour at 37°C to allow the red cells to sediment. The dextran plasma was collected and centrifuged at 450 g for eight minutes. The cells were washed once in saline and suspended in Percoll solution (density 1 070 g/ml) with 5% FCS. The concentration of cells was adjusted to 2 x 108/ml.
PERCOLL GRADIENT PREPARATION
The Percoll gradients were prepared according to the technique of Gartner'3 and Day.'4 Starting with the most dense solution, solutions of decreasing density were layered in a 16 ml polycarbonate tube using a peristaltic pump at low speed. Gradients consisted of 1 X5 ml 1 -100, 3ml 1-900, 3ml 1-085, and 3ml 1-080g/ml. The cells, suspended in Percoll 1'070 g/ml supplemented with 5% FCS as noted above, were layered on top of the gradients (1 x 108 cells in a 2 ml volume per gradient). The tubes including the gradients were then centrifuged at 1600 g for 20 minutes at room temperature.
Cells were harvested from the gradients by 1 ml fractions from the bottoms of the tubes. The density of each fraction was determined and was washed twice in PIPES buffer consisting of 25 mM PIPES, 110 mM NaCl, 5 mM KCI, 40 mM NaOH, and 5'4 mM glucose (pH), '5 then counted in a haemocytometer. Cytocentrifuge smears were prepared from each fraction for differential counts and stained with Wright's stain. Those fractions with the highest purity of eosinophils were pooled and used to examine LTC4 release. More than 95% cell viability was confirmed in all experiments by the trypan blue dye exclusion method.3 '4 Each batch of 106 eosinophils/ml was stimulated with A23187 (2.5 5,M) for 15 minutes after pretreating with PAF (C-18) at concentrations of 1, 5, and 10,uM at 37°C for five minutes. (In our preliminary study LTC4 release from eosinophils was examined after pretreatment with PAF at concentrations between 0-1 and 20 jM which corresponds with previous findings.'6 Eosinophils showed significant responses at PAF concentrations exceeding 1,M, reaching a peak or plateau between 5 and 10 ,uM.) Reactions were stopped by immersion of the tubes in ice and the addition of three volumes of ice cold methanol. The test tubes were immediately centrifuged and the supematant was decanted. The metabolic supematants (containing LTC4 released by cells) were evaporated to dryness under reduced pressure and stored at -70°C until analysis.
PREPARATION FOR HIGH PRESSURE LIQUID
CHROMATOGRAPHY (HPLC) After extraction using a Sep-Pak, the residue was dissolved in the HPLC eluting solvent and injected into a reverse phase-high pressure liquid chromatograph (RP-HPLC) to collect the LTC4 fractions. The recovery rates of LTC4 with this extraction procedure were about 78%. The HPLC system was a Shimadzu LC4A (Kyoto, Japan) equipped with an SPD-2AS spectrophotometric detector. The column was a 2-5 mm x 25 cm Microsorbe RP18 (ODS) (Rainin Instrument Co Inc, Massachusetts, USA). The injection volume was 100 ,l. The solvent comprised acetonitrile, methanol, water, and acetic acid (45:15:39:1). The pH of the solvent was adjusted to 5-6 using HCl and NaOH. The retention time of authentic LTC4 was about 11 minutes. The LTC4 fraction that corresponded to the retention time of authentic LTC4 was collected with a substantial band width on the chromatogram using a fraction collector. '7 18 RADIOIMMUNOASSAY (RIA)
The commercially available radioimmunoassay for LTC4, the LTC4 3H assay reagent system produced by Amersham Corporation (Tokyo, Japan) was obtained from New England Nuclear (Tokyo, Japan) and used as described by the manufacturer with aliquots of selected HPLC fractions. The mean concentration of LTC4 in the supernatants released from eosinophils stimulated by A23187 was significantly greater in the asthmatic patients than in the controls (27 9 (9 9) versus 10-3 (3'7)ng/106 cells, p<0 05) (table 2) .
The amounts of LTC4 in eosinophils from the asthmatic patients produced by A23187 stimulation after pretreatment with PAF (C-18) at concentrations exceeding 1 jiM significantly exceeded that produced by A23187 alone.
The amounts of LTC4 in eosinophils from the healthy donors produced by A23187 stimulation after pretreatment with PAF (C-18) only at concentrations exceeding 1 ,M did not differ significantly from that produced by A23187 alone.
The effect of pretreatment with PAF on LTC4 production by eosinophils from the asthmatic patients was maximum at 5 jM. The amount of LTC4 induced by A23187 after pretreatment with PAF at each of the three different concentrations (1, 5, and 10 gM) was significantly higher in eosinophils from the asthmatic patients than in those from the healthy donors (one factor ANOVA for repeated measures and Scheffe's F test, p<005). The results are summarised in table 2 and the figure.
Discussion
The amount of LTC4 in the eosinophils from the asthmatic patients produced by A23187 stimulation following pretreatment with PAF (C-18) at a concentration exceeding 1 jM was significantly greater than the amount of LTC4 produced by A23187 alone in the eosinophils from both the asthmatic patients and healthy donors. The enhancement was significantly greater in the eosinophils from the asthmatic patients than in those from healthy donors at concentrations exceeding 1 jM.
Fukuda et al '5 showed that hypodense eosinophils (< 1 -082 g/ml) increase in the blood of patients with bronchial asthma and the mean (SD) ofpeak eosinophil density in the asthmatic group was 1 0827 (00035), significantly lower than that of normal subjects (p<0 005 
